Frankfurt Offices Advises Riemser Pharma in Sale of Production Facility and Animal Health Unit

August 13, 2013

Riemser Pharma GmbH agrees to sell its Animal Health Division and its production facility located in the Greifswald-Isle of Riems to IDT Biologika (Riems) GmbH & Co. KG.

It was recently announced that Willkie client Riemser Pharma GmbH agreed to sell its Animal Health Division and its production facility located in the Greifswald-Isle of Riems to IDT Biologika (Riems) GmbH & Co. KG, a wholly owned subsidiary of IDT Biologika GmbH. IDT Biologika plans to manufacture vaccines, mainly for veterinary purposes, at its new subsidiary company in Riems. Research activities for animal health vaccines will also be based at the Riems facility.

Headquartered in Greifswald, Germany, Riemser is a specialty pharmaceutical company that focuses principally on prescription-only human pharmaceuticals in certain therapeutic markets with high medical need, such as Oncology, Anti-infectives and Dermatology. Its products are marketed in Germany and around the world. IDT Biologika is a privately held company with more than 90 years of experience in researching, developing, manufacturing and marketing biologics.

The Willkie deal team, led by partner Mario Schmidt, included national partners Dr. Christian Rolf, Jan Wilms and Dr. Octávio de Sousa, and associates Wolfgang Münchow, Jochen Riechwald, Mario Bammann and Tobias Daubert.